Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphangioleiomyomatosis × Celecoxib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 16 Lung Neoplasms 12 Carcinoma, Non-Small-Cell Lung 12 Breast Neoplasms 12 Head and Neck Neoplasms 8 Rectal Neoplasms 7 Prostatic Neoplasms 7 Mouth Neoplasms 5 Glioblastoma 5 Esophageal Neoplasms 5 Colonic Neoplasms 5 Central Nervous System Neoplasms 5 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Gliosarcoma 4 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma 3 Ovarian Neoplasms 3 Oropharyngeal Neoplasms 3 Neuroblastoma 3 Hypopharyngeal Neoplasms 3 Carcinoma 3 Brain Neoplasms 3 Tongue Neoplasms 2 Salivary Gland Neoplasms 2 Recurrence 2 Precancerous Conditions 2 Neoplasms 2 Nasopharyngeal Neoplasms 2 Medulloblastoma 2

Interventions

Sirolimus 4 Sugars 1 Resveratrol 1 Octreotide 1 Loratadine 1 Letrozole 1 Everolimus 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02484664 2022-01-20

COLA

Brigham and Women's Hospital

Phase 2 Completed

12 enrolled 11 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡